Robert Levy is an Ophthalmology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 Highland Ave
Salem, MA 019707003
Telephone
978-744-1177Provider last certified this registry record 30 Dec 2021.
Clinical trials
- Vasculera in Participants With Lipedema
Sponsor: Primus Pharmaceuticals
- Contingency Management for Opioid and Stimulant Use Disorders in Primary Care
Sponsor: University of Minnesota
- Behavioral Activation for Opioid Use Disorder
Sponsor: University of Minnesota
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Tarsus Pharmaceuticals, Inc.Program year20252 payments
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20252 payments
- Alcon Vision LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
80.2%Prostaglandin Analog50.2%Latanoprost92%Travoprost6%Lumigan2%Part D<11 patientsalpha-Adrenergic Agonist7.8%Brimonidine Tartrate63%Brimonidine Tartrate-Timolol22%Alphagan P8%Combigan8%Part D<11 patients+ 5 more classes in this area
Cardiovascular
7.8%Beta blocker7.8%Timolol Maleate100%Part D≥47 patientsMusculoskeletal
7.1%Cyclooxygenase Inhibitor7.1%Ketorolac Tromethamine100%Part D≥137 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1985–1985 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”